ID   SW1573/S1
AC   CVCL_A5BA
SY   SW-1573/S1; S1
DR   BTO; BTO:0006275
DR   cancercelllines; CVCL_A5BA
DR   Wikidata; Q107116980
RX   PubMed=1348862;
RX   PubMed=1353703;
RX   PubMed=7644478;
RX   PubMed=7809167;
RX   PubMed=12093475;
CC   Population: Caucasian.
CC   Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line).
CC   Sequence variation: Gene deletion; HGNC; 6770; SMAD4; Zygosity=Homozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser33Phe (c.98C>T); ClinVar=VCV000017583; Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Cys (c.34G>T); ClinVar=VCV000012578; Zygosity=Homozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Lys111Glu (c.331A>G); ClinVar=VCV000376482; Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 11103; SMARCB1; Simple; c.362+1G>C; ClinVar=VCV000582116; Zygosity=Heterozygous; Note=Splice donor mutation (from parent cell line).
CC   Derived from site: In situ; Lung; UBERON=UBERON_0002048.
DI   NCIt; C2923; Minimally invasive lung adenocarcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_1720 ! SW1573
SX   Female
AG   44Y
CA   Cancer cell line
DT   Created: 20-05-21; Last updated: 05-10-23; Version: 4
//
RX   PubMed=1348862; DOI=10.1073/pnas.89.8.3498;
RA   Eijdems E.W.H.M., Borst P., Jongsma A.P.M., de Jong S.,
RA   de Vries E.G.E., van Groenigen M., Versantvoort C.H.M.,
RA   Nieuwint A.W.M., Baas F.;
RT   "Genetic transfer of non-P-glycoprotein-mediated multidrug resistance
RT   (MDR) in somatic cell fusion: dissection of a compound MDR
RT   phenotype.";
RL   Proc. Natl. Acad. Sci. U.S.A. 89:3498-3502(1992).
//
RX   PubMed=1353703;
RA   Nieuwint A.W.M., Baas F., Wiegant J., Joenje H.;
RT   "Cytogenetic alterations associated with P-glycoprotein- and
RT   non-P-glycoprotein-mediated multidrug resistance in SW-1573 human lung
RT   tumor cell lines.";
RL   Cancer Res. 52:4361-4371(1992).
//
RX   PubMed=7644478; DOI=10.1073/pnas.92.17.7690;
RA   Zaman G.J.R., Lankelma J., van Tellingen O., Beijnen J.H., Dekker H.,
RA   Paulusma C.C., Oude Elferink R.P.J., Baas F., Borst P.;
RT   "Role of glutathione in the export of compounds from cells by the
RT   multidrug-resistance-associated protein.";
RL   Proc. Natl. Acad. Sci. U.S.A. 92:7690-7694(1995).
//
RX   PubMed=7809167; DOI=10.1073/pnas.91.26.13033;
RA   Muller M., Meijer C., Zaman G.J.R., Borst P., Scheper R.J., Mulder N.H.,
RA   de Vries E.G.E., Jansen P.L.M.;
RT   "Overexpression of the gene encoding the multidrug
RT   resistance-associated protein results in increased ATP-dependent
RT   glutathione S-conjugate transport.";
RL   Proc. Natl. Acad. Sci. U.S.A. 91:13033-13037(1994).
//
RX   PubMed=12093475; DOI=10.1016/S0006-2952(02)00983-8;
RA   Fokkema E., Groen H.J.M., Helder M.N., de Vries E.G.E., Meijer C.;
RT   "JM216-, JM118-, and cisplatin-induced cytotoxicity in relation to
RT   platinum-DNA adduct formation, glutathione levels and p53 status in
RT   human tumour cell lines with different sensitivities to cisplatin.";
RL   Biochem. Pharmacol. 63:1989-1996(2002).
//